Trastuzumab binds HER2 domain IV on tumor cells and engages FcγR-bearing immune effectors (e.g., NK cells) to induce antibody-dependent cellular cytotoxicity (ADCC), leading to lysis/apoptosis of HER2+ cells; signaling blockade is mainly cytostatic.